188 related articles for article (PubMed ID: 33276362)
1. [Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
Kushlinskii NE; Loginov VI; Utkin DO; Filippova EA; Burdennyy AM; Korotkova EA; Pronina IV; Lukina SS; Smirnova AV; Gershtein ES; Braga EA
Mol Biol (Mosk); 2020; 54(6):990-996. PubMed ID: 33276362
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Methylation of 20 miRNA Genes Specifically Involved in Various Steps of Ovarian Carcinoma Spread: From Primary Tumors to Peritoneal Macroscopic Metastases.
Loginov VI; Pronina IV; Filippova EA; Burdennyy AM; Lukina SS; Kazubskaya TP; Uroshlev LA; Fridman MV; Brovkina OI; Apanovich NV; Karpukhin AV; Stilidi IS; Kushlinskii NE; Dmitriev AA; Braga EA
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163224
[TBL] [Abstract][Full Text] [Related]
3. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
5. [MiR-4772 modulates tumor immune microenvironment by regulating immune- related genes in ovarian cancer].
Zhao A; Su Y; Fu D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Nov; 42(11):1638-1645. PubMed ID: 36504056
[TBL] [Abstract][Full Text] [Related]
6. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
7. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
8. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
[TBL] [Abstract][Full Text] [Related]
9. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
Xu S; Tao Z; Hai B; Liang H; Shi Y; Wang T; Song W; Chen Y; OuYang J; Chen J; Kong F; Dong Y; Jiang SW; Li W; Wang P; Yuan Z; Wan X; Wang C; Li W; Zhang X; Chen K
Nat Commun; 2016 May; 7():11406. PubMed ID: 27147225
[TBL] [Abstract][Full Text] [Related]
10. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
[TBL] [Abstract][Full Text] [Related]
12. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of
Koukourakis MI; Kontomanolis E; Sotiropoulou M; Mitrakas A; Dafa E; Pouliliou S; Sivridis E; Giatromanolaki A
Anticancer Res; 2018 Oct; 38(10):5739-5745. PubMed ID: 30275195
[TBL] [Abstract][Full Text] [Related]
13. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Zhu X; Yang H; Lang J; Zhang Y
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
[TBL] [Abstract][Full Text] [Related]
14. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.
Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
[TBL] [Abstract][Full Text] [Related]
17. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.
Tan D; Sheng L; Yi QH
Cancer Biomark; 2018 Feb; 21(2):287-297. PubMed ID: 29171986
[TBL] [Abstract][Full Text] [Related]
18. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
19. The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Zhu X; Zhao L; Lang J
Int J Gynecol Cancer; 2018 Oct; 28(8):1514-1519. PubMed ID: 30045136
[TBL] [Abstract][Full Text] [Related]
20. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
Li D; Wang X; Yang M; Kan Q; Duan Z
Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
